Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 05, 2015 12:24 AM ET


Company Overview of Supernus Pharmaceuticals, Inc.

Company Overview

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products include Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy. The company products also comprise SPN-810, a molindone hydrochloride that has completed Phase II clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIa clinical tri...

1550 East Gude Drive

Rockville, MD 20850

United States

Founded in 2005

309 Employees



Key Executives for Supernus Pharmaceuticals, Inc.

Founder, Chief Executive Officer, President, Secretary and Director
Age: 54
Total Annual Compensation: $485.7K
Chief Financial Officer, Principal Accounting Officer and Vice President
Age: 64
Total Annual Compensation: $317.9K
Chief Medical Officer and Executive Vice President of Research & Development
Age: 63
Total Annual Compensation: $342.4K
Chief Scientific Officer and Senior Vice President of Intellectual Property
Age: 58
Total Annual Compensation: $314.8K
Compensation as of Fiscal Year 2014.

Supernus Pharmaceuticals, Inc. Key Developments

Supernus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revised Earnings Guidance for the Full Year of 2015

Supernus Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $35,052,000 against $29,675,000 a year ago. Operating income was $3,076,000 against $3,756,000 a year ago. Net income was $2,005,000 or $0.03 per basic and diluted share against $3,202,000 or $0.08 per basic and diluted share a year ago. For the six months, the company reported total revenues of $63,185,000 against $38,756,000 a year ago. Operating income was $6,507,000 against loss of $9,667,000 a year ago. Net income was $2,923,000 or $0.06 per basic and diluted share against net loss of $12,342,000 or $0.30 per basic and diluted share a year ago. The company is updating its full year 2015 financial guidance for both expected net product sales and operating income. The company expects that net product sales will range from $135 million to $140 million, with operating income ranging from $8 million to $10 million. This compares to prior guidance of net product sales of $130 million to $140 million and operating income of $6 million to $10 million. The company continues to expect that research and development expenses will increase by greater than 50% in 2015 as compared to 2014 as the company progresses the development of SPN-810 and SPN-812.

Supernus Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 04, 2015

Supernus Pharmaceuticals, Inc. announced that they will report Q2, 2015 results on Aug 04, 2015

Supernus Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Supernus Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Similar Private Companies By Industry

Company Name Region
Patheon Pharmaceuticals Inc. United States
Nexgen Pharma, Inc. United States
Legacy Pharmaceuticals Puerto Rico, LLC United States
Panacela Labs, Inc. United States
Octamer Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Supernus Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at